LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
Podcasts & Webcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
BioCentury-BayHelix China Healthcare Summit
East-West Healthcare Reception
BioCentury-BayHelix East-West Summit
Bio€quity Europe
BioCentury Grand Rounds Inquiry
Grand Rounds U.S.
Grand Rounds Europe
The BioCentury Show
Webinars - Upcoming & On-Demand
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Feb 26, 2021
Distillery Therapeutics
FOXI1, CAII inhibition to treat tuberous sclerosis complex-associated kidney cysts
DISEASE CATEGORY: Renal
INDICATION: Renal damage Targeting transcription factor FOXI1 or downstream target CAII, a cytoplasmic carbonic anhydrase, could treat kidney cysts associated with tuberous
Read More
BioCentury
|
Jan 12, 2021
Deals
Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more
Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases
Read More
BioCentury
|
Apr 18, 2018
Distillery Techniques
Disease models
Read More
BioCentury
|
Dec 13, 2016
Distillery Therapeutics
Cancer
Read More
BioCentury
|
Apr 23, 2015
Distillery Therapeutics
Therapeutics: Mammalian target of rapamycin complex 1 (mTORC1); tuberous sclerosis complex tumor suppressor 1 (TSC1)
Read More
BioCentury
|
Mar 27, 2014
Strategy
Explaining the exceptions
Read More
BioCentury
|
Dec 13, 2012
Cover Story
Translating autism
Read More
BioCentury
|
Sep 6, 2012
Distillery Therapeutics
Indication: Cancer
Read More
BioCentury
|
Mar 24, 2011
Distillery Techniques
Technology: Disease models
Read More
BioCentury
|
Dec 4, 2008
Cover Story
New strategies for CNS regeneration
Read More
Items per page:
10
1 - 10 of 13
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa
Help